Technology, vast amounts of information, and advances in data are creating opportunities to predict, prevent, and personalize treatment that were once unimaginable. Even pessimistic estimates show that the potential annual savings from the use of predictive medicine worldwide will amount to $26 billion, according to a report by strategy&, the global strategy division of the PwC network.

Using precision molecular diagnostics or pharmacogenetics for six common conditions – cancer, diabetes, heart disease, hypertension, lung disease and stroke – has huge potential for disease prevention by identifying people at risk and facilitating preventive treatment, US researchers have found.

Thus, a 10% reduction in morbidity through predictive medicine over the next 50 years would generate between $33 billion and $114 billion in economic value, depending on the condition, in the form of longer, healthier lives, the PwC analysis shows.

What does the transition to predictive medicine entail?

A well-developed prognostic health care system requires medical support of the population, integrated into everyday life. This would include understanding a person’s genetic susceptibility to disease and risk factors, epigenetic markers and relevant biomarkers, preventive measures such as screening and regular monitoring of health and well-being.

Read the rest of the article on the PwC Romania blog

The article is signed by Ruxandra Tarlescu, partner of PwC in Romania

Article supported by PwC Romania